» Articles » PMID: 27311615

(-)-Rhazinilam and the Diphenylpyridazinone NSC 613241: Two Compounds Inducing the Formation of Morphologically Similar Tubulin Spirals but Binding Apparently to Two Distinct Sites on Tubulin

Overview
Publisher Elsevier
Specialties Biochemistry
Biophysics
Date 2016 Jun 18
PMID 27311615
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The most potent microtubule assembly inhibitor of newer diphenylpyridazinone derivatives examined was NSC 613241. Because NSC 613241 and (-)-rhazinilam also induce the formation of similar 2-filament spirals, these aberrant reactions were compared. Spiral formation with both compounds was enhanced by GTP and inhibited by GDP and by 15 other inhibitors of microtubule assembly. Similarly, microtubule assembly induced by paclitaxel or laulimalide is enhanced by GTP and inhibited by GDP and assembly inhibitors, but neither [(3)H]NSC 613241 nor [(3)H](-)-rhazinilam bound to microtubules or inhibited the binding of [(3)H]paclitaxel or [(3)H]peloruside A to microtubules. Differences in the pitch of aberrant polymers were found: NSC 613241-induced and (-)-rhazinilam-induced spirals had average repeats of 85 and 79-80 nm, respectively. We found no binding of [(3)H]NSC 613241 or [(3)H](-)-rhazinilam to αβ-tubulin dimer, but both compounds were incorporated into the polymers they induced in substoichiometric reactions, with as little as 0.1-0.2 mol compound/mol of tubulin, and no cross-inhibition by NSC 613241 or (-)-rhazinilam into spirals occurred. Under reaction conditions where neither compound induced spiral formation, both compounds together synergistically induced substantial spiral formation. We conclude that (-)-rhazinilam and NSC 613241 bind to different sites on tubulin that differ from binding sites for other antitubulin agents.

Citing Articles

Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment.

Guo Y, Wang H, Gerberich J, Odutola S, Charlton-Sevcik A, Li M Cancers (Basel). 2021; 13(19).

PMID: 34638255 PMC: 8507561. DOI: 10.3390/cancers13194769.


Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Liu L, OKelly D, Schuetze R, Carlson G, Zhou H, Trawick M Molecules. 2021; 26(9).

PMID: 33925707 PMC: 8125421. DOI: 10.3390/molecules26092551.


Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Risinger A, Du L Nat Prod Rep. 2019; 37(5):634-652.

PMID: 31764930 PMC: 7797185. DOI: 10.1039/c9np00053d.

References
1.
Gamble W, Durso N, Fuller R, Westergaard C, Johnson T, Sackett D . Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem. 1999; 7(8):1611-5. DOI: 10.1016/s0968-0896(99)00089-9. View

2.
David B, Sevenet T, Morgat M, Guenard G, Moisand A, TOLLON Y . Rhazinilam mimics the cellular effects of taxol by different mechanisms of action. Cell Motil Cytoskeleton. 1994; 28(4):317-26. DOI: 10.1002/cm.970280405. View

3.
Gradishar W . The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep. 2010; 13(1):11-6. DOI: 10.1007/s11912-010-0145-9. View

4.
Hamel E, del Campo A, Lowe M, Lin C . Interactions of taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization. J Biol Chem. 1981; 256(22):11887-94. View

5.
Timasheff S, Andreu J, Na G . Physical and spectroscopic methods for the evaluation of the interactions of antimitotic agents with tubulin. Pharmacol Ther. 1991; 52(2):191-210. DOI: 10.1016/0163-7258(91)90008-a. View